News

Sanofi Signs a Letter of Intent With Tricog Health for AI-Enabled Cardiac Diagnostics — Global Pharma Meets India's Leading Cardiac AI Platform

By Mustafa Shariff, Editor in Chief · September 10,2026 · 2 mins read

Mustafa Shariff, Editor in Chief — Sanofi Signs a Letter of Intent With Tricog Health for AI-Enabled Cardiac Diagnostics — Global Pharma Meets India's Leading Cardiac AI Platform

Summary

  • Sanofi Signs LOI With Tricog Health for AI-Enabled Cardiac Diagnostics — Global Pharma and India's Leading Cardiac AI Platform Partner
  • Sanofi signed a Letter of Intent with Bengaluru-based Tricog Health (InstaECG, InstaEcho) for AI-enabled cardiac diagnostics on September 8, 2026 — combining Sanofi's cardiovascular pharma expertise with Tricog's 24/7 cloud-connected AI cardiac interpretation platform.

"Tricog's InstaECG platform has solved a problem that cardiologists in India have been grappling with for decades: how do you bring clinically accurate, cardiologist-verified cardiac diagnostics to remote clinics, rural primary health centres, and smaller hospitals that don't have an on-site cardiologist? AI-powered cloud-connected ECG interpretation, verified by our team of cardiologists 24 hours a day, seven days a week, delivers a certified report in minutes from any location in India. Sanofi's partnership brings global pharmaceutical expertise in cardiovascular disease management to complement Tricog's diagnostic AI — creating a partnership that addresses cardiac health from identification through to treatment."

Sanofi, the French global pharmaceutical company, signed a Letter of Intent with Bengaluru-based Tricog Health for AI-enabled cardiac diagnostics on September 8, 2026, per a report by Digital Health News. The LOI brings together Sanofi's global cardiovascular disease expertise with Tricog's India-built AI-powered cardiac diagnostic platform — a pharma-AI diagnostics convergence that reflects the growing intersection of pharmaceutical companies and clinical AI in India's healthcare market.
What Tricog Health Does
Tricog Health was founded to solve one of India's most acute clinical problems: cardiovascular disease is India's largest cause of premature death, and early and accurate cardiac diagnosis is the most impactful intervention — yet the cardiologists needed to interpret ECGs are concentrated in large city hospitals, leaving rural clinics, smaller hospitals, and remote primary health centres without cardiac diagnostic capability.
Tricog's InstaECG platform addresses this directly: a cloud-connected ECG device installed at a clinic or hospital transmits electrocardiogram data to Tricog's central platform, where a combination of AI algorithms and Tricog's in-house team of cardiologists analyse the ECG and return a certified cardiac diagnostic report within minutes — 24 hours a day, seven days a week. The pay-per-use business model makes the service affordable for smaller healthcare providers. Tricog also offers InstaEcho for AI-enabled echocardiogram (echo) interpretation, extending its cardiac diagnostic platform beyond ECG to heart structure and function assessment.
Sanofi's Cardiovascular Portfolio Context
Sanofi has one of the world's most established cardiovascular pharmaceutical portfolios — including Plavix (clopidogrel, antiplatelet), Praluent (alirocumab, PCSK9 inhibitor for LDL reduction), and a range of cardiovascular risk management products. In India, Sanofi's cardiovascular business serves both hospital and primary care market segments. A partnership with Tricog's AI cardiac diagnostics platform enables Sanofi to connect its cardiovascular therapy prescriptions to the diagnostic moments that precede treatment decisions — creating a diagnosis-to-treatment continuum that benefits both patient outcomes and commercial positioning.
The LOI Stage and What It Means
A Letter of Intent (LOI) is the first formal step in a commercial partnership — a mutually signed document confirming both parties' intention to negotiate and execute a definitive agreement. It is not yet a signed commercial contract. The LOI signals that Sanofi and Tricog have agreed on the strategic direction of their partnership and are proceeding toward definitive terms. BHC Media will report on the commercial agreement when it is executed.
BHC Perspective
At Bengaluru Health Community, the Sanofi-Tricog LOI is the cardiac AI-pharma convergence story that BHC's digital health and MedTech community should understand as a commercial model. For BHC founders building AI diagnostic platforms — the Sanofi-Tricog LOI demonstrates how an AI diagnostics company can create a partnership value proposition for a global pharmaceutical company: diagnostic-to-treatment pathway integration that benefits both the AI company's commercial reach and the pharma company's therapy positioning.
Frequently Asked Questions
Q: What is the Sanofi-Tricog LOI?
A: A Letter of Intent signed September 8, 2026, for AI-enabled cardiac diagnostics — Sanofi (global cardiovascular pharma) partnering with Bengaluru-based Tricog Health (InstaECG AI cardiac diagnostics platform). LOI is the first formal step; a definitive commercial agreement is to follow.
Q: What is Tricog Health's InstaECG?
A: A cloud-connected ECG device deployed at remote clinics, smaller hospitals, and diagnostic centres — transmits ECG data to Tricog's central platform where AI algorithms and in-house cardiologists analyse and return a certified cardiac diagnostic report within minutes, 24/7. Pay-per-use model. Also offers InstaEcho for echocardiogram AI interpretation.
Q: Why is Sanofi partnering with an AI diagnostics company?
A: Sanofi's cardiovascular therapy portfolio (Plavix, Praluent) benefits from connection to the diagnostic moments that precede treatment decisions. Tricog's AI cardiac diagnostics platform extends Sanofi's reach into remote and primary care settings where cardiac disease is detected — creating a diagnosis-to-treatment continuum.